Pfizer Inc. closed 16.17% below its 52-week high of $31.54, which the company achieved on July 30th.

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...

The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.

West Virginia Attorney General (AG) Patrick Morrisey announced a total $17 million settlement agreement with pharmaceutical companies, Pfizer and Ranbaxy after more than a decade of litigation ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...

The general mood among these heavyweight investors is divided, with 33% leaning bullish and 50% bearish. Among these notable ...

Pfizer Inc. ( NYSE:PFE ) will increase its dividend from last year's comparable payment on the 7th of March to ...

We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look ...

U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...

At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...

The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from ...

Court revives lawsuit against Pfizer's diversity fellowship Group claims Pfizer program discriminates against white, ...